Business / Finance

RSS

Bruker first quarter revenue increases 13.6% to $405.6 million

Bruker Corporation today reported financial results for the first quarter ended March 31, 2012.

2 May 2012

AmerisourceBergen acquires World Courier Group

AmerisourceBergen Corporation today announced that it has completed the previously announced acquisition of World Courier Group, Inc., a privately held leading global specialty transportation and logistics provider for the biopharmaceutical industry.

2 May 2012

CR2 announces acquisition of CardioReady

CR2, LLC announced the acquisition of CardioReady, a pioneer in Cardiac Emergency Response and Automated External Defibrillator (AED) deployment since 2004. Using a patented suite of solutions, CardioReady assists organizations across the United States in protecting the lives of their customers, employees, and other visitors to their sites against Sudden Cardiac Arrest (SCA) – the leading cause of death in America.

30 Apr 2012

Humana reports drop in first quarter profits

The insurer attributed the decrease to paying out more in claims, as well as additional investment as it anticipates strong growth in its Medicare Advantage plans.

30 Apr 2012

GE Capital provides $7.5M in senior secured credit facilities to PharmAthene

GE Capital, Healthcare Financial Services announced today that it was sole lender and administrative agent on $7.5 million in senior secured credit facilities for PharmAthene, consisting of a $2.5 million term loan and a $5 million revolving line of credit.

30 Apr 2012

Covidien acquires PolyTouch Medical

PolyTouch Medical Ltd., a leading developer of hernia mesh placement technologies, was acquired by Covidien, a leading global provider of healthcare products that is traded on the New York Stock Exchange at a current market value of $26 billion.

30 Apr 2012

Watson first quarter net income increases 87% to $208.8 million

Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.

30 Apr 2012

Hologic second quarter revenues increase 7.4% to $471.2 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the second fiscal quarter ended March 24, 2012.

From Hologic, Inc. 30 Apr 2012

Hologic enters definitive agreement to acquire Gen-Probe

Hologic, Inc. and Gen-Probe Incorporated today announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion.

From Hologic, Inc. 30 Apr 2012

Humana first quarter consolidated revenues increase 11% to $10.22B

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2012 (1Q12) of $1.49, compared to $1.86 per share for the quarter ended March 31, 2011 (1Q11). The company had previously anticipated earnings per share in the range of $1.35 to $1.45 for 1Q12.

30 Apr 2012

LifePoint Hospitals first quarter revenues increase 12.2% to $851.0 million

LifePoint Hospitals, Inc. today announced results for the first quarter ended March 31, 2012.

30 Apr 2012

Magellan reports net revenue of $773.2 million for first quarter 2012

Magellan Health Services Inc. today reported financial results for the first quarter 2012, as summarized below. For the quarter ended March 31, 2012, the company reported net revenue of $773.2 million, segment profit of $55.4 million, and net income of $20.8 million or $0.75 per diluted common share.

30 Apr 2012

Judge rejects trade groups' effort to stall Express Scripts-Medco deal

A U.S. district judge denied an effort by trade groups representing pharmacies and drugstore chains to halt Express Scripts' acquisition of Medco Health Solutions until their lawsuit to block the deal is reviewed.

27 Apr 2012

Watson enters definitive agreement to acquire Actavis

Watson Pharmaceuticals, Inc. and Actavis Group today jointly announced that Watson has entered into a definitive agreement to acquire privately held Actavis for approximately EUR4.25 billion upfront.

27 Apr 2012

Asahi Kasei acquires ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the successful completion of its acquisition of ZOLL Medical Corporation, a major US manufacturer of medical devices for critical care, on April 26, 2012, US Eastern time.

27 Apr 2012

Allied Healthcare increases stake in Coridon to over 44%

Allied Healthcare Group (ASX: AHZ) announced today that post the recent capital raising it has invested a further $1 million into Coridon, increasing its holding in the company to 44.4%. Allied has increased its investment in Coridon as the Company progresses towards its Phase I study for a herpes vaccine and makes further progress on its HPV therapeutic vaccine program.

26 Apr 2012

Great Lakes NeuroTechnologies secures funding for development and testing of innovative neurotechnology

Great Lakes NeuroTechnologies Secures Over $4.5 Million in Funding to Fuel New Product Development for Parkinson's Disease and Neuroscience Education April 24, 2012: Valley View, OH - Great Lakes NeuroTechnologies announced today they have secured over $4.5 million is funding for new product development. The funding includes three new projects sponsored by the National Institutes of Health's SBIR program. Each project is focused on developing and testing innovative neurotechnology. Two projects focus on the monitoring and treatment of Parkinson's disease while another will develop a wireless physiological monitor and web-based teaching system for high school neuroscience courses.

26 Apr 2012

AstraZeneca first quarter revenue down 11% to $7,349 million

First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGATM (dapagliflozin) in Europe.

26 Apr 2012

Report identifies strategies necessary to improve marketplace for LLINs

The universal coverage campaign for bed nets succeeded in dramatically extending access to these life-saving products, though recent gains may be in jeopardy unless rapid action is taken. Over 560 million long-lasting insecticide-treated nets (LLINs) are required through 2015 alone to achieve and maintain universal coverage in Africa, at a total global cost of $2.4 billion.

26 Apr 2012